Live feed08:30:00·4mPRReleasevia QuantisnowTempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformByQuantisnow·Wall Street's wire, on your screen.TEM· Tempus AI Inc.PSNL· Personalis Inc.TechnologyHealth Care
